Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06679413 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

A Phase 1 study, sponsored by UCB Biosciences.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT06679413: Completed Phase 1 study, sponsored by UCB Biosciences.

NCT06679413 is a Phase 1 study that has completed, run by UCB Biosciences. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06679413, a Phase 1 study, has completed, sponsored by UCB Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008

Primary Outcome

Cmax is the maximum observed plasma concentration of Midazolam alone and in combination with ZX008 at steady state.

Interventions

  • DRUG metformin
  • DRUG midazolam
  • DRUG bupropion
  • DRUG fenfluramine HCl

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-12-04
Est. Completion 2025-06-12
Phase Phase 1
UCB Biosciences

39 total trials

What the finished NCT06679413 record still lists

NCT06679413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.

NCT06679413 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06679413 about?

NCT06679413 is a clinical study titled "A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants". The purpose of the study is to assess the single-dose pharmacokinetics (PK) of 3 probe drugs (midazolam, bupropion, and metformin) before and after repeat doses of ZX008

What is the current status of trial NCT06679413?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-12-04. Estimated completion is 2025-06-12.

What interventions are being tested in trial NCT06679413?

The interventions under investigation include: metformin (DRUG), midazolam (DRUG), bupropion (DRUG), fenfluramine HCl (DRUG).

Who is sponsoring clinical trial NCT06679413?

This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06679413's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06679413, the US trial registry maintained by the National Library of Medicine. NCT06679413 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.